Actively Recruiting
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Led by Ruijin Hospital · Updated on 2025-06-18
30
Participants Needed
1
Research Sites
259 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the efficacy, safety and tolerability of radiotherapy and chemotherapy, apatinib with camrelizumab in the neoadjuvant (prior to surgery) and adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
CONDITIONS
Official Title
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Previously untreated localized gastric or GEJ adenocarcinoma defined by T3-4N+M0
- Plans to have surgery after pre-operative chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Adequate organ function
- Male participants of childbearing potential agree to use contraception during the study and for 120 days after last dose
- Female participants of childbearing potential agree to use contraception during the study and for 120 days after last dose
- Life expectancy greater than 12 months
You will not qualify if you...
- Uncontrolled hypertension (systolic 6140 mmHg or diastolic 690 mmHg) despite antihypertensive therapy
- Known hypersensitivity to study drugs or excipients
- Known hereditary or acquired bleeding and thrombotic disorders
- Congenital or acquired immune deficiency (e.g., HIV infection)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
S
Shu-Bei Wang, MD
CONTACT
G
Gang Cai, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here